← All trials
NCT03235141
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2017
- Primary completion
- Oct 30, 2017
- Completion date
- Dec 30, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityReponsible party - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Panacea Technology Co.，LtdCollaborator
- Zhuhai Essex Bio-Pharmaceutical Company LimitedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.